SOURCE: Lipomics Technologies Inc.

September 25, 2006 09:00 ET

Lipomics Technologies Hires New Director of Finance and Operations

WEST SACRAMENTO, CA -- (MARKET WIRE) -- September 25, 2006 -- Lipomics Technologies, Inc., a company specializing in the comprehensive and quantitative profiling of lipid metabolites, today announced that Scott Van Buskirk has joined the company in the newly created position of Director of Finance and Operations.

"Scott brings 30 years of experience in growing early stage companies in the medical device and diagnostics industry," said Steve Watkins, Ph.D., Lipomics' president and chief scientific officer. "He was part of the senior management team at EndoTherapeutics and UroSystems, both successfully divested to major medical device companies. He has extensive consulting experience in operations, finance and marketing, and supporting emerging companies from seed stage through market introduction. Scott will add practical business perspective and a range of skills that will be invaluable to us as we convert our technologies into commercially available diagnostics."

"I am excited to be part of an enterprise with such a broad range of opportunities," said Scott Van Buskirk, director of finance and operations at Lipomics. "The science here is solid and I look forward to being a part of this team."

Van Buskirk holds an undergraduate degree in Political Science and an MBA from the St. Mary's College Executive MBA program.

About Lipomics Technologies, Inc.

Lipomics develops tools for drug discovery and personalized medicine using proprietary technologies for lipid metabolism analysis and data interpretation. We generate a comprehensive understanding of lipid metabolism from plasma, serum or tissue samples by combining quantitative measurements of lipid metabolites with proprietary algorithms for mapping the lipomic profiles to biochemical pathways. In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technology to speed drug discovery processes, improve clinical trial stratification, reduce late-stage drug attrition, discover new biomarkers and develop early tests for monitoring drug response. More information about Lipomics can be found at

Contact Information

    Sarina Chohan
    (916) 371-7974
    Email Contact

    Agency Contact
    Doug Forsyth
    Alchymia Communications® LLC
    (541) 482-8744
    Email Contact